Catalyst Pharmaceuticals, Inc.

Total Valuation

Catalyst Pharmaceuticals, Inc. carries a market capitalization of 3.83B, placing it among publicly traded companies globally. Its enterprise value stands at 2.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Catalyst Pharmaceuticals, Inc. currently has 122.18M shares outstanding.

Valuation Ratios

Catalyst Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 13.70. The price-to-sales ratio is 5.08, and the price-to-book ratio stands at 5.79.

Enterprise Valuation

On an enterprise value basis, Catalyst Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.45 and an EV/FCF ratio of 10.94. The EV/Sales ratio of 3.82 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.52 provides insight into valuation relative to core operating earnings.

Financial Position

Catalyst Pharmaceuticals, Inc. maintains a current ratio of 7.10, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Catalyst Pharmaceuticals, Inc. posts a return on equity of 51.14 and a return on invested capital of 38.09.

Taxes

Over the trailing twelve months, Catalyst Pharmaceuticals, Inc. has paid 75.14M in income taxes, reflecting an effective tax rate of 25.34.

Stock Price Statistics

Catalyst Pharmaceuticals, Inc.'s stock has gained approximately 25.57206% over the past 52 weeks. The 50-day moving average sits at 28.00, while the 200-day moving average is 23.77.

Income Statement

Over the trailing twelve months, Catalyst Pharmaceuticals, Inc. generated 596.96M in revenue and converted that into 221.32M in net income, yielding earnings per share of 1.74. EBITDA reached 305.83M, while operating income came in at 267.64M.

Balance Sheet

Catalyst Pharmaceuticals, Inc. holds 755.86M in cash and equivalents against 2.68M in total debt, resulting in a net debt position of -755.86M. Total book value stands at 523.47M, with working capital of 807.99M providing operational flexibility.

Cash Flow

Catalyst Pharmaceuticals, Inc. produced 208.21M in operating cash flow over the past twelve months. After subtracting -85,000.00 in capital expenditures, free cash flow totaled 208.13M - equivalent to 1.70 per share.

Margins

Catalyst Pharmaceuticals, Inc. operates with a gross margin of 85.96, reflecting its pricing power and cost economics. The operating margin of 44.83 and net profit margin of 37.08 provide insight into operational efficiency.

Dividends & Yields

Scores

Catalyst Pharmaceuticals, Inc. posts an Altman Z-Score of 16.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.